Last Updated: November 16, 2026

Details for Patent: 9,555,048

« Back to Dashboard


Which drugs does patent 9,555,048 protect, and when does it expire?

Patent 9,555,048 protects ZILRETTA and is included in one NDA.

This patent has fifty-one patent family members in twenty-two countries.

Summary for Patent: 9,555,048
Title:Corticosteroids for the treatment of joint pain
Abstract:Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
Inventor(s):Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
Assignee: Pacira Therapeutics Inc
Application Number:US14/461,884
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;
Patent landscape, scope, and claims:

US Patent 9,555,048: Scope, Claims, Expiration, and Zilretta Patent Landscape

US Patent 9,555,048 protects a method of treating pain or inflammation with injectable, controlled-release triamcinolone acetonide microparticles. The claim requires a specific PLGA polymer profile, a 22% to 28% triamcinolone loading, and sustained corticosteroid release. The patent is closely associated with Flexion Therapeutics' Zilretta, an extended-release intra-articular triamcinolone acetonide product later acquired by Pacira BioSciences.

The patent's principal commercial value is concentrated in the formulation combination rather than in triamcinolone acetonide itself. The strongest infringement risk applies to injectable PLGA microsphere products that reproduce the claimed drug loading, polymer molecular weight, lactic acid:glycolic acid ratio, particle size, and sustained-release characteristics.

What does US Patent 9,555,048 protect?

US 9,555,048 is a method-of-treatment patent. Its independent claim requires all of the following:

Claim limitation Required scope
Therapeutic use Treatment of pain or inflammation
Dosage form Injectable formulation
Delivery system Controlled- or sustained-release microparticles
Active ingredient Triamcinolone acetonide, or a pharmaceutically acceptable salt
Polymer matrix PLGA
TCA loading 22% to 28% of the microparticles
PLGA molecular weight About 40 to 70 kDa
PLGA composition Lactic acid:glycolic acid molar ratio of 80:20 to 60:40

The patent does not broadly cover every injectable triamcinolone formulation. A competing product using a suspension, liposome, hydrogel, implant, non-PLGA carrier, or a TCA loading outside the claimed range would not literally satisfy claim 1.

The patent's commercial center is a microsphere formulation containing approximately 25% triamcinolone acetonide in a 75:25 PLGA matrix. Zilretta is supplied as a 32 mg extended-release intra-articular triamcinolone acetonide formulation for osteoarthritis pain of the knee. The FDA-approved product uses PLGA microspheres and is reconstituted before intra-articular injection.[1]

How do the claims of US 9,555,048 operate?

Claim 1: Core formulation and treatment combination

Claim 1 is the controlling claim. It combines a treatment step with detailed formulation specifications. A potential infringer must administer the formulation to a patient, but the formulation must also meet the microsphere, TCA-content, and PLGA limitations.

This structure creates several potential design-around positions:

  • Use a TCA concentration below 22% or above 28%.
  • Use PLGA with a molecular weight below 40 kDa or above 70 kDa.
  • Use a lactic acid:glycolic acid ratio outside the 80:20 to 60:40 range.
  • Replace PLGA with another biodegradable polymer.
  • Deliver TCA through a nonmicroparticle formulation.
  • Use a formulation that does not provide controlled or sustained release.

The doctrine of equivalents could still create litigation risk where a product falls narrowly outside a numerical limitation, but the numerical ranges provide a comparatively clear claim-construction framework.

Claims 2 and 9: Preferred PLGA chemistry

Claim 2 narrows the polymer ratio to 75:25 lactic acid:glycolic acid. This limitation is commercially important because 75:25 PLGA is a conventional composition for long-acting biodegradable microspheres and is associated with the Zilretta formulation.

Claim 9 adds an inherent viscosity range of 0.3 to 0.5 dL/g. Inherent viscosity functions as a proxy for polymer molecular weight and solution behavior. It can become a disputed issue in litigation because testing conditions, solvent selection, temperature, and measurement methodology can affect the result.

Claims 4, 5, and 6: Intra-articular administration and duration

Claims 4 and 5 expressly require one or more intra-articular injections. These claims are narrower than claim 1 and are the most directly aligned with Zilretta's FDA-approved use.

Claim 6 requires release of TCA for at least 14 days and up to 90 days after administration to a joint. The claim covers a duration range rather than a single release profile. A product with a release period shorter than 14 days would not meet the literal limitation.

Claim 7 adds a functional limitation requiring release for at least 14 days at a rate that does not adversely suppress the hypothalamic-pituitary-adrenal axis. This limitation may create factual disputes over clinical testing, pharmacokinetics, and what constitutes adverse HPA-axis suppression.

Claims 8, 10, and 11: Dose, particle size, and PEG

Claim 8 narrows the TCA content to a total load dose of 10 to 50 mg. The 32 mg Zilretta dose falls within that range.

Claim 10 covers microparticles with a mean diameter of 10 to 100 micrometers. Particle size is relevant to injection performance, syringeability, tissue retention, and release kinetics.

Claim 11 covers microparticles containing a PEG moiety. The stated range, "between 25% to 0% weight percent," should be read as a range from 0% to 25% by weight. The wording is internally awkward and could create an interpretation issue, but it is directed to PEG-containing or PEG-modified particles.

What diseases and indications are covered by US 9,555,048?

Claims 12 through 20 expand the patient and disease categories. The claimed indications include:

Category Examples in the claims
Arthritic disease Osteoarthritis, rheumatoid arthritis, gouty arthritis, juvenile arthritis, psoriatic arthritis, ankylosing spondylitis
Joint and soft tissue disorders Bursitis, tenosynovitis, epicondylitis, Morton's neuroma, synovitis
Spine and nerve pain Sciatica, radicular arm, neck, lumbar and thoracic pain, spinal stenosis, back pain
Dermal disorders Alopecia areata, keloids, psoriasis, lichen planus, granuloma annulare
Allergic and inflammatory diseases Asthma, dermatitis, allergic rhinitis, serum sickness, drug hypersensitivity
Autoimmune and systemic disorders Systemic lupus erythematosus, dermatomyositis, polymyositis, sarcoidosis
Hematologic and oncologic uses Leukemias, lymphomas, hemolytic anemia, thrombocytopenia
Neurologic and other conditions Multiple sclerosis exacerbations, cerebral edema, tuberculosis meningitis, postoperative pain and swelling

The broad disease list does not eliminate the formulation limitations in claim 1. A product must still be an injectable controlled-release TCA microparticle formulation using the specified PLGA characteristics.

Claims 13 through 20 are vulnerable to written-description, enablement, and obviousness challenges if asserted against uses far removed from intra-articular therapy. The commercial strength of the patent is greater for joint injections than for the full systemic and dermatologic indication list.

When does US Patent 9,555,048 expire?

Event Date or status
Patent US 9,555,048
Issue date January 31, 2017
Patent type Utility patent
Patent term basis Twenty years from the earliest effective nonprovisional filing date, subject to adjustment
Expected expiration May 2032, subject to official term adjustment and terminal-disclaimer analysis
Product association Zilretta, extended-release triamcinolone acetonide
Patent landscape Part of the Flexion/Pacira extended-release TCA estate

The operative expiration date should be confirmed against the USPTO Patent Center and the FDA Orange Book listing because patent-term adjustment can change the ordinary twenty-year calculation. Patent expiration does not automatically authorize commercial launch if other listed patents, regulatory exclusivities, injunctions, or approval requirements remain relevant.[2][3]

What is the Orange Book status of US 9,555,048?

The patent has been associated with Zilretta's FDA patent listings. Orange Book relevance depends on whether the patent claims the approved drug, an approved method of use, or both. For Zilretta, the most important listed claims are those directed to extended-release triamcinolone acetonide microspheres administered by intra-articular injection.

An ANDA applicant seeking approval before expiration would generally need to address listed patents through one of the following certifications:

  • Paragraph I: No patent information has been submitted.
  • Paragraph II: The patent has expired.
  • Paragraph III: The applicant will market only after patent expiration.
  • Paragraph IV: The patent is invalid, unenforceable, or will not be infringed.

A Paragraph IV notice would expose the applicant to Hatch-Waxman litigation. The filing of a qualifying patent-infringement action within 45 days can trigger a statutory stay of FDA approval for up to 30 months, subject to statutory exceptions.[4]

Zilretta's complex injectable microsphere formulation also creates a technical barrier that is separate from Orange Book patent risk. A conventional ANDA must demonstrate pharmaceutical equivalence and bioequivalence, while long-acting injectable products can require difficult in vitro release, particle characterization, device, and pharmacokinetic comparisons.

What related patents protect Zilretta and extended-release triamcinolone?

The relevant patent estate should be analyzed as a family rather than through US 9,555,048 alone.

Patent category Likely protected subject matter Commercial relevance
Composition patents TCA-loaded PLGA microspheres Core product protection
Method patents Treating pain and inflammation with the microspheres Orange Book and litigation relevance
Intra-articular claims Injection into a joint and release over 14 to 90 days Closest to approved Zilretta use
Process patents Microsphere manufacture, solvent removal, drying, and particle control Manufacturing barriers
Formulation patents Excipients, PEG, reconstitution systems, and syringeable suspensions Design-around and product-line protection
Follow-on patents Additional release profiles, doses, or indications Potentially later expiration dates

Public patent records should be reviewed for continuations, divisionals, and continuation-in-part applications. A continuation can issue after US 9,555,048 and carry claims that are narrower but commercially more useful, particularly claims directed to the 32 mg intra-articular product or defined manufacturing conditions.

How strong is the patent estate for Zilretta?

The estate is strongest against a directly substitutable extended-release TCA microsphere product using PLGA and a similar drug loading.

Strengths

  1. The core claim contains multiple physical and chemical limitations that map closely to the commercial product.
  2. The 22% to 28% TCA range captures the commercially relevant approximately 25% loading.
  3. The 40 to 70 kDa molecular-weight range and 60:40 to 80:20 polymer ratio narrow the formulation to a technically meaningful class.
  4. Dependent claims cover the 75:25 PLGA ratio, 10 to 100 micrometer particle size, 10 to 50 mg dose, and intra-articular delivery.
  5. The patent is directed to a complex injectable system that is harder to reproduce than an immediate-release steroid suspension.

Weaknesses

  1. The patent is a method patent, not a broad composition-of-matter patent covering TCA.
  2. A competitor may pursue a polymer system, drug loading, particle size, or release profile outside the claimed ranges.
  3. Several claims use functional or performance language that may require extensive testing to prove infringement.
  4. The broad disease list may face written-description and enablement scrutiny if asserted beyond the specification's demonstrated embodiments.
  5. Prior-art risk is substantial because PLGA microspheres, sustained-release corticosteroids, and intra-articular steroid treatment were established technologies before the relevant filing period.

What generic entry risks exist for Zilretta?

A generic or follow-on entrant faces four separate risk layers:

Risk Assessment
Patent infringement High for a product copying the 25% TCA, 75:25 PLGA platform
Bioequivalence High technical burden because microsphere release kinetics are product-defining
Manufacturing High because particle size, residual solvent, encapsulation efficiency, and release profile must be controlled
Regulatory pathway More complex than a standard immediate-release injectable; the appropriate pathway may depend on FDA product classification and reference-product requirements

A Paragraph IV challenger could avoid literal infringement by changing the PLGA ratio or TCA loading. That strategy would shift the dispute toward the doctrine of equivalents, formulation performance, and whether the modified product remains pharmaceutically equivalent to Zilretta.

A 505(b)(2) pathway could be relevant for a differentiated long-acting TCA injectable, but it would not eliminate patent litigation risk. The applicant would still need to address listed patents and demonstrate safety, efficacy, and quality for the proposed product.

Which companies are challenging or competing with Zilretta?

Zilretta competes primarily with conventional intra-articular corticosteroids, including immediate-release triamcinolone acetonide products marketed by multiple generic manufacturers. Those products are not necessarily direct patent challengers because they do not use the claimed controlled-release PLGA microsphere technology.

The more relevant competitive categories are:

  • Generic immediate-release triamcinolone acetonide injections.
  • Other intra-articular corticosteroids.
  • Hyaluronic acid products.
  • Platelet-rich plasma and other procedural treatments.
  • Extended-release or depot corticosteroid formulations.
  • Regenerative and nonsurgical osteoarthritis therapies.

A conventional triamcinolone injection generally does not practice claim 1 because it lacks PLGA controlled-release microparticles. It may compete commercially while remaining outside the patent's literal scope.

What litigation and licensing events affect the patent landscape?

Flexion Therapeutics was acquired by Pacira BioSciences in 2021 in a transaction valued at approximately $1.375 billion. The acquisition transferred Zilretta and Flexion's related intellectual property and commercial rights to Pacira.[5]

The acquisition is commercially important because Pacira has an economic incentive to enforce the patent estate through the period before expected expiration. The principal legal questions for any challenger would be infringement of the formulation limitations, validity of the numerical ranges, enablement of the broad indication claims, and the regulatory status of the proposed product.

No separate commercial license is necessary to explain current Zilretta ownership. Pacira is the relevant commercial patent owner or successor-in-interest for the Flexion Zilretta portfolio.

What is the revenue exposure from US 9,555,048?

The patent protects a product with material commercial value to Pacira, but it does not protect the entire intra-articular corticosteroid market. Revenue exposure is therefore product-specific.

Zilretta sales have been reported as a distinct product category in Pacira's public filings. The product's value depends on continued differentiation from low-cost immediate-release corticosteroids, physician adoption, reimbursement, and the absence of a therapeutically substitutable long-acting generic.[5]

The commercial impact of a successful challenge would likely be asymmetric:

  • A direct generic microsphere product could materially reduce Zilretta pricing.
  • An immediate-release steroid competitor would have less direct impact because it already competes without practicing the patent.
  • A noninfringing long-acting formulation could reduce Zilretta share without invalidating US 9,555,048.
  • Loss of the core patent before 2032 would increase the probability of accelerated price erosion.

Key Takeaways

  • US 9,555,048 is a method patent covering injectable sustained-release TCA microparticles in a defined PLGA matrix.
  • The central commercial embodiment is approximately 25% TCA in 75:25 PLGA, consistent with Zilretta.
  • The patent claims treatment, not TCA generally and not every corticosteroid injection.
  • Claims 4 through 10 provide important protection for intra-articular delivery, release duration, dose, viscosity, and particle size.
  • The expected patent-term endpoint is in May 2032, subject to official patent-term adjustment.
  • Direct generic entry faces both patent risk and substantial complex-injectable development risk.
  • Immediate-release triamcinolone products compete with Zilretta but generally do not fall within claim 1.
  • Pacira's acquisition of Flexion made Pacira the principal commercial stakeholder in the Zilretta patent estate.

FAQs About US Patent 9,555,048 and Zilretta

Is US 9,555,048 a composition patent?

No. Its principal independent claim is a method-of-treatment claim requiring administration of a specified injectable TCA/PLGA microparticle formulation.

Does a standard triamcinolone acetonide injection infringe US 9,555,048?

Generally, no. A standard immediate-release injection lacks the claimed controlled-release PLGA microparticle matrix.

Does the patent cover all intra-articular corticosteroid injections?

No. It covers intra-articular administration only when the formulation satisfies the claimed TCA loading, PLGA molecular-weight, polymer-ratio, and microparticle requirements.

Can a competitor avoid the patent by using a different biodegradable polymer?

A different polymer would not literally satisfy the PLGA limitation in claim 1. Equivalence and infringement risk would depend on the product's technical characteristics and the specific claim asserted.

Is Zilretta protected by patents beyond US 9,555,048?

Yes. Zilretta is associated with a broader patent family and related formulation, process, and method-of-use rights. The complete freedom-to-operate analysis requires review of all issued patents, pending continuations, Orange Book listings, and foreign counterparts.

References

  1. U.S. Food and Drug Administration. (2017). Zilretta (triamcinolone acetonide extended-release injectable suspension) prescribing information. FDA.

  2. United States Patent and Trademark Office. (2017). U.S. Patent No. 9,555,048: Methods and compositions for treatment of pain and inflammation. USPTO.

  3. United States Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent No. 9,555,048. USPTO.

  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

  5. Pacira BioSciences, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,555,048

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pacira Pharms Inc ZILRETTA triamcinolone acetonide FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR 208845-001 Oct 6, 2017 RX Yes Yes ⤷  Start Trial ⤷  Start Trial METHOD OF TREATING PAIN OR INFLAMMATION WITH AN INJECTABLE CONTROLLED OR SUSTAINED RELEASE FORMULATION OF TRIAMCINOLONE ACETONIDE ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,555,048

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 082471 ⤷  Start Trial
Australia 2011285691 ⤷  Start Trial
Australia 2012290683 ⤷  Start Trial
Australia 2015268647 ⤷  Start Trial
Australia 2017245408 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.